A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy

Sang Hoon Park, Yoon Tae Jeen, Hwang Rae Chun, Dong Il Kim, Chang Won Baeck, Yong Sik Kim, Hoon Jai Chun, Hong Sik Lee, Soon Ho Um, Jai Hyun Choi, Chang Duck Kim, Ho Sang Ryu, Jin Hai Hyun

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Crohn's disease is a chronic inflammatory bowel disease which affects mainly children and young adults, and its cause remains unknown so far. Infliximab, a monoclonal antibody to the pivotal cytokine tumor necrosis factor-alpha, has been approved as a drug for both induction and maintenance therapy for moderately to severely active, or fistula-complicated Crohn's disease. The authors report a 12-year-old male patient diagnosed as Crohn's disease complicated with a perianal fistula, which was refractory to the conventional therapy. After the 0, 2, and 6 week scheduled intravenous infusion of infliximab, the patient reached to clinical remission in both subjective symptoms and objective manifestations. For children or young adults who develop Crohn's disease in a refractory course, infliximab may serve as a drug which leads to a clinical improvement or even to an extent of remission.

Original languageEnglish
Pages (from-to)297-301
Number of pages5
JournalThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Volume46
Issue number4
Publication statusPublished - 2005 Oct

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy'. Together they form a unique fingerprint.

  • Cite this